Veristat in the Press
May 2026
- How bispecific antibodies are reshaping oncology development | Drug Discovery & Development | May 20, 2026
- Veristat Extends Regulatory and Clinical Services to Companies Focused on Europe | Medical Product Outsourcing | May 18, 2026
- Veristat Unveils InStat, an AI Biostatistics Platform to Reduce Clinical Trial Data Readout Time from 5 Weeks to 5 Days Without Regulatory Risks | Health Tech Insiders | May 15, 2026
- Veristat launches AI biostatistics platform to accelerate clinical trial data readouts | Discover Pharma | May 15, 2026
- Veristat Launches AI Biostatistics Platform, Cutting Clinical Trial Data Readout Time from 5 Weeks to 5 Days* Without Regulatory Risks | International Clinical Trials | May 14, 2026
- Veristat launches AI platform for faster trials | BioXconomy/Clinical Insider | May 14, 2026
- Veristat Launches AI Biostatistics Platform, Cutting Clinical Trial Data Readout Time from 5 Weeks to 5 Days* Without Regulatory Risks | Biotech News Network | May 13, 2026
- Veristat bolsters regulatory, medical writing services with $135m Certara buy | Clinical Insider / BioXconomy (Informa) | May 7, 2026
- Q&A: How Chinese Biopharma Is Navigating Western Regulatory Markets | IN VIVO, part of Citeline publications | May 7, 2026
April 2026
- Veristat: Acquisition Of Certara’s Regulatory And Medical Writing Business Expands Capabilities Across Drug Development Lifecycle | Pulse 2.0 | April 28, 2026
- Veristat to Acquire Certara's Regulatory and Medical Writing Business in Expansion of CRO Capabilities | Applied Clinical Trials | April 28, 2026
- Radnor drug designer Certara sells medical writing business | MSN.com | April 24, 2026
- Veristat acquires Certara regulatory and medical writing business | Discover Pharma | April 23, 2026
- Veristat to Acquire Certara’s Regulatory and Medical Writing Business | Biospace | April 22, 2026
- Veristat to Acquire Certara’s Regulatory and Medical Writing Business | Boston Biotech Networks | April 21, 2026
- Certara sells business unit for up to $135M in first major deal under new CEO | Philadelphia Business Journal | April 22, 2026
- Veristat to Acquire Certara Regulatory and Medical Writing Unit | City Biz (Syndicated in Boston, Philly, NYC) | April 22, 2026
- WindRose-Backed Veristat Buys Certara’s Regulatory and Medical Writing Business | Mergers & Acquisitions | April 22, 2026
- Certara to sell regulatory writing unit to Veristat for $135M | Investing.com | April 22, 2026
- Certara Shares Rise Amid Plan to Sell Portion of Business to Veristat | Market Watch | April 22, 2026
- Veristat, LLC signed a definitive agreement to acquire Regulatory and Medical Writing business of Certara, Inc. for approximately $140 million. | MarketScreener | April 22, 2026
- Certara to Sell Global Medical Writing Business to Veristat for $100M, Plus Up to $35M Earn-Out | Trading View | April 22, 2026
- Certara agrees to sell regulatory unit to Veristat for up to $135 million | Street Insider | April 22, 2026
- Certara (NASDAQ: CERT) divests regulatory and medical writing unit to Veristat | Stock Titan | April 22, 2026
- Certara to sell regulatory and medical writing business for up to $135M | Seeking Alpha | April 21, 2026
- Certara (CERT) News Today | Market Beat | April 21, 2026
- Veristat Acquires Certara's Regulatory Writing Business to Expand European Market Services | Nova Pharma News | April 21, 2026
- Fast, accurate drug development: Rentschler Biopharma is harnessing AI-driven automation to stay competitive | Worcester Business Journal | April 20, 2026
- Veristat Discovers a Goldmine of Opportunities in China | Clinical Research News | April 16, 2026
- What if the most innovative industry in the world is running on 40-year-old thinking? | Life Sciences Today & Health IT News | April 13, 2026
- China's $13B pharma boom drives growth but faces hurdles in US and EU regulatory and market access | Bioprocess International | April 6, 2026
March 2026
- From Data Collection to Decision-Making in Clinical Trials | Scrip/Citeline | March 31, 2026
- Executive Q&A with Kim on AI and modernization of Veristat | Pharmaceutical Outsourcing | March 25, 2026
- Chinese drugmakers target EU approval to unlock global markets, says Veristat | BioXconomy | March 18, 2026
- Veristat Broadens Regulatory and Clinical Support for Chinese Drug and Device Developers Expanding Overseas | The Machine Maker (India) | March 16, 2026
- Veristat expands global trial & regulatory services as Chinese drugmakers push overseas | Indian Pharma Post | March 14, 2026
- Veristat expands regulatory and clinical services to Chinese drugmakers | The Pharma Letter | March 12, 2026
- Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets | Biospace | March 12, 2026
- Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets | Pharmiweb | March 12, 2026
- Veristat Expands Regulatory and Clinical Services to Chinese Drug and Device Companies Seeking Efficient Way to Enter European Markets | The Pharma Data | March 11, 2026
- Improving clinical trials: Veristat’s first female CEO plans to double revenue, workforce | Worcester Business Journal | March 9, 2026
- Opinion: Navigating the FDA After the Storm To Advance Drug Candidates | Biospace | March 2, 2026
February 2026
- Voices of SCOPE: From Talk to Tangible Change | Voices of Scope series | February 17, 2026
- How Veristat is Adapting Its Approach to Clinical Trials | Pharmaceutical Executive (and ACT) | February 13, 2026
- Expanding Focus on Data Analytics, Automation, and Early-Stage Strategic Consulting | Pharmaceutical Executive (and ACT) | February 12, 2026
- Southborough clinical research firm names new CEO | Worcester Business Journal | February 12, 2026
- Veristat Welcomes New CEO | Medical Product Outsourcing | February 12, 2026
- 2026 cell and gene therapy predictions | Cell & Gene Therapy Review | February 11, 2026
- Addressing Key Barriers for Women in STEM | Pharmaceutical Executive (and ACT) | February 11, 2026
- Scope Summit Interview with CEO Kim Boericke | Open Door Salon | February 6, 2026
- Kim Boericke takes the helm as Veristat CEO: Driving innovation, diversity, and patient-centric growth in life sciences | BioXconomy/Clinical Insider (part of Informa) | February 6, 2026
January 2026
- Changing Faces: Pharma and biotech, January 2026 | Pharmaphorum | January 29, 2026
- Industry Leaders Predict Life Science Trends for 2026 | The Scientist | January 27, 2026
- Healthcare Data – 2026 Health IT Predictions | Healthcare IT Today | January 23, 2026
- Only 1 in 25 orgs confident third-party risk assessment aligns with actual risk, AI and automation are top investment priority for 56% of orgs, plus 27 more stories | Healthcare IT Today | January 18, 2026
- Veristat Names Industry Veteran Kim McLean Boericke as New Chief Executive Officer | Healthcare Business | January 18, 2026
- Veristat names Kim McLean Boericke as CEO to drive next phase of clinical research growtheristat names Kim McLean Boericke as CEO to drive next phase of clinical research growth | Discover-Pharma | January 15, 2026
- Appointments and advancements for Jan. 13, 2026 | Bioworld | January 14, 2026
- Veristat Names Kim McLean Boericke as CEO | Contract Pharma | January 14, 2026
- Veristat Names Industry Veteran Kim McLean Boericke as New Chief Executive Officer | Biospace + Biospace Mass | January 14, 2026
- Veristat Names Industry Veteran Kim McLean Boericke as New CEO | Pharma Outsourcing | January 14, 2026
- Business Wire Life Sciences News (US) | Bio Florida | January 14, 2026
- Veristat Names Industry Veteran Kim McLean Boericke as New Chief Executive Officer | The AI Journal | January 14, 2026
- Boston Cambridge Biotech News | Boston Biotech Networks | January 14, 2026
- Veristat Appoints Kim McLean Boericke as CEO | City Biz (in Boston area) | January 13, 2026
- Inside 2026: The Industry’s AI Turning Point | The Medicine Maker | January 7, 2026
- Trendspotting: Embracing AI, DEI Changes, Restrategizing Research Sites | Clinical Research News | January 6, 2026